Biotech entity
funding is the sole category represented across all 1 tracked stories. Alexandria Real Estate Equities is most often covered alongside BNP Paribas Exane, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Alexandria Real Estate Equities, all published on August 12, 2026.
Last mentioned: Aug 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
funding is the sole category represented across all 1 tracked stories. Alexandria Real Estate Equities is most often covered alongside BNP Paribas Exane, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Alexandria Real Estate Equities, all published on August 12, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 11 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Alexandria Real Estate Equities. Shared-story counts are live from our verified record — not editorial picks.
As the dominant landlord to pharma and startup labs, Alexandria’s FY 2026 EPS guidance of $6.35-$6.45—and its Q2 revenue beat of $662.78M—carry major implications for R&D real estate costs. While lease rates keep rising, a -36% net margin hints at stress in the sector that could eventually impact tenant concessions and space availability.
Source: dailypolitical.com · tickerreport.com
Alexandria Real Estate Equities is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
